Project Grant R43HL187059
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $306K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Santa Clara, CA 95054, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded MDC Studio, Inc. $309,813 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an automated vascular access device that enables less-experienced providers to safely and reliably perform central venous and arterial cannulation. The R61 phase focuses on automating the core steps of successful cannulation. MDC Studio will design, construct, and test sensors and automation to detect blood vessel...
- The National Heart, Lung, and Blood Institute awarded Inflo Medical Inc. $595,332 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize its MOBYBOX extracorporeal membrane oxygenation (ECMO) platform for pediatric use. Inflo Medical is redesigning the MOBYBOX's gas exchanger and pulsatile displacement pump to reduce thrombogenicity and hemolysis in pediatric patients. The Phase I Small Business Innovation Research effort focuses on two complementary...
- The National Heart Lung and Blood Institute awarded Precisionbio AI, LLC $374,472 on September 1, 2026, to develop a machine learning-driven precision dosing system for warfarin anticoagulation therapy under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will develop and validate a predictive platform that integrates lifestyle, clinical, and pharmacogenomic data through a multi-model ensemble combining interpretable machine learning models with deep neural networks and...
- The National Heart, Lung, and Blood Institute awarded Pulsentry, Inc. $309,198 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and prototype an automated detection system for cardiac tamponade using existing fingertip pulse oximeters. Pulsentry will develop machine learning algorithms that analyze pulse waveform perturbations to identify early signs of cardiac tamponade, a medical emergency caused by fluid or clot accumulation around the heart...
- The National Heart, Lung, and Blood Institute awarded Aventusoft LLC $500,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance commercialization of HEMOLINK, a skin-adhered disposable patch for non-invasive hemodynamic monitoring. HEMOLINK is a first-in-class wearable medical device featuring a synchronous quad-sensor array designed to estimate left ventricular end-diastolic pressure (LVEDP) for remote cardiac monitoring. The patch incorporates...
- The National Heart, Lung, and Blood Institute awarded $598,636 to Spheric Bio Inc. on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop the EMULAATE platform, a patient-specific left atrial appendage occlusion (LAAO) device for stroke prevention in atrial fibrillation patients. Spheric Bio is developing EMULAATE to assemble fully soft, personalized implants directly inside the patient's body through a minimally invasive approach by delivering,...
- The National Heart, Lung, and Blood Institute awarded Environment & Health Group Inc. $314,321 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop HeartSense.AI, a generative AI-driven mobile health solution for hypertension self-management in lower-income adults. The application describes an mHealth platform that integrates a generative AI model with home-based blood pressure monitoring, digital pill reminders, and non-physician-led telehealth to...
- The National Heart, Lung, and Blood Institute awarded $920,616 to Vena Vitals Inc. on September 24, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop VeriSleep, a wearable device for continuous, non-invasive blood pressure monitoring during sleep as a cardiovascular biomarker. The project addresses the technological gap in continuous blood pressure measurement during sleep, where current intermittent cuff-based monitors leave lengthy unmonitored gaps despite the...
- The National Heart, Lung, and Blood Institute awarded Prenosis, Inc. $1,218,102 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate the Heart Failure CardioScore, an artificial intelligence diagnostic tool for acute heart failure in emergency department patients. Prenosis will combine novel biomarkers and clinical data with machine learning to improve diagnostic and prognostic accuracy for acute heart failure, addressing the challenge...